No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CERT240517C10000
- 6.15
- -1.33-17.78%
15min DelayClose May 17 15:59 ET
6.15High6.15Low
6.15Open7.48Pre Close5 Volume16 Open Interest10.00Strike Price3.08KTurnover6239.21%IV3.54%PremiumMay 17, 2024Expiry Date6.08Intrinsic Value100Multiplier0DDays to Expiry0.07Time Value100Contract SizeAmericanOptions Type0.8849Delta0.0242Gamma2.42Leverage Ratio-33.4105Theta0.0000Rho2.14Eff Leverage0.0003Vega
Intraday
- 5D
- 1D
News
Drug Discovery Informatics Market Worth $8.17 Billion by 2031: Global Industry Analysis Featuring Profiles of Certara, Infosys, Collaborative Drug Discovery, Jubliant Biosys, Curia Global
Analysts Offer Insights on Healthcare Companies: Certara (CERT), Exact Sciences (EXAS) and AbCellera Biologics (ABCL)
Certara Analyst Maintains Hold Rating Amid Mixed Financial Performance and Strategic Developments
Certara, Inc. (NASDAQ:CERT) Q1 2024 Earnings Call Transcript
Q1 2024 Certara Inc Earnings Call
Express News | Certara Shares Are Trading Lower After the Company Reported Q1 Financial Results
Comments
The fact that Certara is now generating some pre-tax profits from its prior investments is very encouraging. The promising trends warrant this stock for further investigation despite its current low returns compared to the industry average.
Returns At Certara (NASDAQ:CERT) Are On The Way Up 1
Acquisition of Applied BioMath by Certara could enhance QSP biosimulation adoption in life sciences, revolutionizing drug invention. This may impact the drug discovery process, improving decisions and reducing late stage attrition rates.
Amid less promising revenue projections, Certara's surprisingly high P/S ratio indicates investor hopes for a business rebound. However, analysts remain skeptical, suggesting shareholders may face disappointment if the P/S ratio rebalances with growth outlook.
Pre-Market Stock Movers
Gapping up
$Fabrinet(FN.US$
(Fabrinet surged 21% after its fiscal fourth-quarter results late Monday topped analysts' estimates. The advanced manufacturing services company posted non-GAAP earnings of $1.86 per share, greater than the $1.80 earnings per share expected by analysts polled by FactSet. Revenue came in at $655.9 million, greater than the $641.4 million consensus estimate.)
$Applovin(APP.US$
...
Gapping up
$Fabrinet(FN.US$
(Fabrinet surged 21% after its fiscal fourth-quarter results late Monday topped analysts' estimates. The advanced manufacturing services company posted non-GAAP earnings of $1.86 per share, greater than the $1.80 earnings per share expected by analysts polled by FactSet. Revenue came in at $655.9 million, greater than the $641.4 million consensus estimate.)
$Applovin(APP.US$
...
22
1
$Bridger Aerospace(BAER.US$ $Couchbase(BASE.US$ $Certara(CERT.US$ $Coherus BioSciences(CHRS.US$ $Torrid(CURV.US$ $Dollar General(DG.US$ $EPAM Systems(EPAM.US$ $First Horizon National(FHN.US$ $Forza X1(FRZA.US$ $GameStop(GME.US$ $MGO Global(MGOL.US$ $Altria(MO.US$ $Mondee Holdings(MOND.US$ $Rent the Runway(RENT.US$ $Smartsheet(SMAR.US$ $Semtech(SMTC.US$
1
1
Read more